Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V937 and Pembrolizumab in Advanced Solid Tumors
NCT04521621Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Primary completion
- Jul 2023
- Modality
- Oncolytic Viruses, Microbiome Therapeutics
- Countries
- 14
01
Overview
A Phase 2 trial of gebasaxturev in triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), cutaneous squamous cell carcinoma (cSCC), hepatocellular carcinoma (HCC), Gastric carcinoma (GC), sponsored by Merck & Co.. Started Oct 2020; status: terminated.
02
Drugs
gebasaxturev
03
Conditions
triple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)cutaneous squamous cell carcinoma (cSCC)hepatocellular carcinoma (HCC)Gastric carcinoma (GC)
Beyond the preview
Go deeper on NCT04521621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521621.